COVID-19 vaccination in Malaysia

Background: One and a half years after the official end of the COVID-19 pandemic, assessing disease patterns and immunization outcomes is still critical. The purpose of this study is to look into the epidemiology of COVID-19 in Malaysia, as well as to evaluate the effectiveness and side effects of the three locally available vaccines.
Methods: The data for this study were gathered from publicly available databases on the Malaysian Ministry of Health's official website. The principal statistical tests used were the Kruskal-Wallis test and one-way ANOVA. The results showed that the COVID-19 booster dose had the greatest influence on lowering mortality rates.
Results: While minor side effects were recorded in just 2.2% of instances, the AstraZeneca vaccination had much greater rates of muscular discomfort, joint pain, and chills than the Pfizer and Sinovac vaccines. Adults aged 40 and up faced much lower risks, with age-specific studies revealing lower vulnerability in children and protective effects in older adults.
Conclusion: The booster dose is an important public health strategy that contributes significantly to the reduction of COVID-19 deaths. It is extremely advised to continue giving booster doses, especially to high-risk populations.